LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Compugen Ltd

Fechado

1.73 2.37

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.69

Máximo

1.76

Indicadores-chave

By Trading Economics

Rendimento

-1.1M

-7.2M

Vendas

813K

2.3M

P/E

Médio do Setor

60.333

51.198

EPS

-0.08

Margem de lucro

-314.405

Funcionários

74

EBITDA

-12M

-7.5M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+302.3% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-546M

140M

Abertura anterior

-0.64

Fecho anterior

1.73

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Compugen Ltd Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de jun. de 2025, 14:31 UTC

Ganhos

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

6 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

6 de jun. de 2025, 20:33 UTC

Ganhos

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 de jun. de 2025, 19:36 UTC

Conversa de Mercado

Oil Futures Post Solid Weekly Gains -- Market Talk

6 de jun. de 2025, 19:28 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 de jun. de 2025, 18:46 UTC

Conversa de Mercado

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 de jun. de 2025, 18:02 UTC

Conversa de Mercado

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 de jun. de 2025, 16:35 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 de jun. de 2025, 16:34 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 de jun. de 2025, 16:21 UTC

Conversa de Mercado

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

6 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

6 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

6 de jun. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

6 de jun. de 2025, 16:07 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

6 de jun. de 2025, 16:07 UTC

Conversa de Mercado

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 de jun. de 2025, 15:53 UTC

Conversa de Mercado

Mexican Inflation Seen Rising in May -- Market Talk

6 de jun. de 2025, 15:36 UTC

Conversa de Mercado

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 de jun. de 2025, 15:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 de jun. de 2025, 15:33 UTC

Conversa de Mercado

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 de jun. de 2025, 15:16 UTC

Conversa de Mercado

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 de jun. de 2025, 15:05 UTC

Conversa de Mercado

Silver at its Highest In Nearly 15 Years -- Market Talk

6 de jun. de 2025, 14:35 UTC

Conversa de Mercado

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 de jun. de 2025, 14:28 UTC

Conversa de Mercado

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 de jun. de 2025, 14:28 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 de jun. de 2025, 14:28 UTC

Conversa de Mercado

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 de jun. de 2025, 14:15 UTC

Conversa de Mercado

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 de jun. de 2025, 14:12 UTC

Ganhos

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 de jun. de 2025, 14:09 UTC

Ganhos

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparação entre Pares

Variação de preço

Compugen Ltd Previsão

Preço-alvo

By TipRanks

302.3% parte superior

Previsão para 12 meses

Média 7 USD  302.3%

Máximo 10 USD

Mínimo 4 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Compugen Ltd - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

3

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.25 / 1.48Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.